TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Jenving Clinical Trial Services AB
Closing information (x1000 EUR)
| Closing information | 2025/12 | 2024/12 | 2023/12 |
| Turnover |
126
|
107 | |
| Financial expenses |
0
|
0 | |
| Earnings before taxes |
38
|
18 | |
| EBITDA |
37
|
17 | |
| Total assets |
172
|
159 | |
| Current assets |
117
|
113 | |
| Current liabilities |
15
|
18 | |
| Equity capital |
145
|
130 | |
| - share capital |
4
|
5 | |
| Employees (average) |
1
|
1
|
1 |
Financial ratios
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Solvency |
84.3%
|
81.8% | |
| Turnover per employee |
126
|
107 | |
| Profit as a percentage of turnover |
30.2%
|
16.8% | |
| Return on assets (ROA) |
22.1%
|
11.3% | |
| Current ratio |
780.0%
|
627.8% | |
| Return on equity (ROE) |
26.2%
|
13.8% | |
| Change turnover |
23
|
3 | |
| Change turnover % |
-8%
|
22%
|
2% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2025/12 | 2024/12 | 2023/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.